Leaderboards/Lung Cancer Research Studies

Lung Cancer Research Studies

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Papers

Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges

Frontiers in Immunology|2024

102 cit.

Publication in Nature Communications (2025) [88 citations, W4408152119]

Nature Communications|2025

88 cit.

Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer

Cancer Cell|2024

46 cit.

Publication in Molecular Cancer (2024) [41 citations, W4399192972]

Molecular Cancer|2024

41 cit.

Adjuvant icotinib for resected EGFR-mutated stage II–IIIA non-small-cell lung cancer (ICTAN, GASTO1002): a randomized comparison study

Signal Transduction and Targeted Therapy|2025

4 cit.

Navigating treatment combinations in small-cell lung cancer

Nature Medicine|2024

3 cit.

Publication in Molecular Cancer (2025) [2 citations, W4416895230]

Molecular Cancer|2025

2 cit.

Publication in Cancer Research (2026) [W7148702084]

Cancer Research|2026

0 cit.

Publication in Cancer Research (2026) [W7148832621]

Cancer Research|2026

0 cit.

Emerging Leaders

Drafting the new consensus

Researchers

Lynnette Fernandez‐Cuesta

Centre international de recherche sur le cancer

Sidney Kimmel Comprehensive Cancer Center

Denys Pominchuk

Kyiv City Clinical Oncology Center

Ziad Hanhan

Riverview Medical Center

Zhen Zhang

Sun Yat-sen University

Weiping Ma

Icahn School of Medicine at Mount Sinai

Triparna Sen

The Ohio State University

Wenchu Lin

Chinese University of Hong Kong, Shenzhen

Papers

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer

JAMA|2022

456 cit.

Therapy-induced APOBEC3A drives evolution of persistent cancer cells

Nature|2023

145 cit.

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology

Journal for ImmunoTherapy of Cancer|2023

142 cit.

WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC

Cell Reports|2022

131 cit.

Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC

Journal of Thoracic Oncology|2023

106 cit.

Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity

Nature Genetics|2023

83 cit.

Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer

Nature Cancer|2022

69 cit.

KDM6A epigenetically regulates subtype plasticity in small cell lung cancer

Nature Cell Biology|2023

69 cit.

CircVAPA promotes small cell lung cancer progression by modulating the miR-377-3p and miR-494-3p/IGF1R/AKT axis

Molecular Cancer|2022

66 cit.

Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts

Nature Communications|2022

53 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

Eric P. Krenning

Cyclotron (Netherlands)

Jeffrey A. Engelman

Cancer Research Center

Roman K. Thomas

University of Cologne

John D. Minna

Center for Neuro-Oncology

Julien Sage

Stanford University

Alice T. Shaw

Dana-Farber Cancer Institute

Nagahiro Saijo

National Cancer Center Hospital East

David H. Johnson

Texas A&M University

Lauren A. Byers

The University of Texas MD Anderson Cancer Center

Stephen V. Liu

Georgetown University

Papers

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

New England Journal of Medicine|2006

5.8k cit.

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Science|2007

4.5k cit.

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Science Translational Medicine|2011

3.6k cit.

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

New England Journal of Medicine|2018

3.5k cit.

Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer

New England Journal of Medicine|2013

3.4k cit.

Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors

New England Journal of Medicine|2017

3.2k cit.

Comprehensive genomic profiles of small cell lung cancer

Nature|2015

2.4k cit.

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

New England Journal of Medicine|2014

2k cit.

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

Journal of Clinical Oncology|2009

1.9k cit.

Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide

New England Journal of Medicine|1999

1.5k cit.

Reagents for Lung Cancer Research Studies

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

VEGF Bioassay

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 61

Menin (E5P1R) Rabbit Monoclonal Antibody

Cited in 13 papers

#19893$178,415

View Evidence →

Cell Signaling TechnologyEvidence 65

Phospho-Rb (Ser807/811) (D20B12) Rabbit Monoclonal Antibody (Pacific Blue™ Conjugate)

Cited in 10 papers

#75864$493

View Evidence →

Cell Signaling TechnologyEvidence 66

LshCas13a/C2c2 (Leptotrichia shahii) (7D1-H7) Mouse Monoclonal Antibody

Cited in 10 papers

#43731$158,348

View Evidence →

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 67

COL3A1 Antibody

Cited in 34 papers

#30565$317

View Evidence →

Cell Signaling TechnologyEvidence 66

FXR2 Antibody

MASH1